Turn Therapeutics (TTRX) Treasury Shares (2025 - 2026)

Turn Therapeutics' (TTRX) quarterly Treasury Shares came in at $61882.0 in Q1 2026, up 54.71% quarter-over-quarter from $40000.0 in Q4 2025.

Turn Therapeutics (TTRX) Treasury Shares (2025 - 2026) Analysis & Trends

Turn Therapeutics' Treasury Shares history runs 2 years deep, the most recent figure standing at $61882.0 for Q1 2026.

On a quarterly basis, Treasury Shares changed N/A year-over-year to $61882.0 in Q1 2026; TTM through Mar 2026 was $61882.0, a N/A change from a year earlier, with the FY2025 full-year figure at $40000.0, changed N/A from the prior year.
Treasury Shares climbed to $61882.0 in Q1 2026 per TTRX's latest filing, from $40000.0 in the prior quarter.
Across five years, Treasury Shares topped out at $61882.0 in Q1 2026 and bottomed at $40000.0 in Q4 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Treasury Shares (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-	-21,709.08
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-	265,401.92
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn	-
4	NuCana	279.75 Bn	279.75 Bn	-	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn	-
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn	19.41 Bn
7	Belite Bio	62.51 Bn	62.51 Bn	-	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn	-
9	Revolution Medicines	37.78 Bn	37.78 Bn	-	5.14 Mn
10	Turn Therapeutics	282.39 Mn	282.39 Mn	-	61,882.00

Download Data